Press Release: Canada Approves Proton Pump Inhibitor, Pariet (Rabeprazole), for Treatment of H. Pylori Infection
Tuesday November 4, 2003
Health Canada has just approved a new indication for Pariet* (rabeprazole sodium) tablets, a fast-acting prescription medication that is in a class called Proton Pump Inhibitors (PPI).
Canada Approves Proton Pump Inhibitor, Pariet (Rabeprazole), for Treatment of H. Pylori Infection
TORONTO, ON -- November 4, 2003 -- If you're suffering from painful ulcers, it may not be the spicy food that is to blame, but a type of ulcer-causing bacterium that is found in the gastrointestinal tract. Health Canada has just approved a new indication for Pariet* (rabeprazole sodium) tablets, a fast-acting prescription medication that is in a class called Proton Pump Inhibitors (PPI).
When taken in combination with appropriate antibiotics, Pariet* helps get rid of Helicobacter pylori (H. pylori), a bacterium that causes more than 90 per cent of ulcers of the small intestine.1 An estimated 20 to 40 per cent of the Canadian population carries the H. pylori bacterium in either their small intestine or stomach and an estimated 10 to 20 per cent (up to 2.5 million) of these people may develop clinically relevant disease requiring medical treatment.2
"Many of my patients complain of heartburn pain and discomfort from gastrointestinal problems, such as ulcers," says Dr. Lawrence Cohen, an associate professor of medicine at the University of Toronto. "Sometimes they think the pain is caused by spicy foods. Contrary to popular belief, eating certain foods does not cause ulcers. Ulcers can be caused by a more serious condition, such as H. pylori infection."
In acid suppression studies, Pariet* has shown that it is fast and effective.3,4 When used in combination with antibiotics to wipe out H. pylori associated with ulcers of the small intestine, Pariet* offers doctors and their patients an effective and safe treatment option when used according to its approved prescribing information.5,6
H. pylori
Researchers are not certain how people contract H. pylori, but they think it may be through food or water or through oral contact such as kissing.7 Getting rid of H. pylori in patients with ulcers of the small intestine facilitates healing, reduces the rate of recurrence and reduces the risk of ulcer bleeding.2 The stomach's lining contains millions of cells with "acid pumps" that help digest food. Proton Pump Inhibitors, or PPIs, work by decreasing the acid produced by these pumps, keeping acid production under control. Suppressing the acid that the stomach produces helps the antibiotics eliminate the H. pylori bacteria.8 In Canada, the recommended therapy for the eradication of H. pylori includes treatment with a Proton Pump Inhibitor and appropriate antibiotics.9
"Today, we know the importance of eradicating of H. pylori. Proton pump inhibitors, such as Pariet*, along with appropriate antibiotics, can successfully eradicate the infection in most patients and allow ulcers of the duodenum (the first part of the small intestine) to heal, as well as lower the chance of ulcers coming back," says Dr. Cohen.
Pariet*
Pariet* was first approved in Canada in May 2001 for the healing of stomach ulcers, duodenal ulcers, reflux esophagitis (a severe form of heartburn) and symptom relief of reflux conditions, such as heartburn and regurgitation. Pariet* tablets may also be used in rare conditions like "Zollinger-Ellison" syndrome, where the stomach produces large amounts of acid.
References:
1. Centers for Disease Control and Prevention (CDC) Electronic references. Retrieved July 22, 2003 from http://www.cdc.gov/ulcer/.
2. Chaun H. Update on the role of H pylori infection in gastrointestinal disorders. Can J Gastroenterol Vol. 15, No. 4, April 2001:251-255.
3. Williams MP, Sercombe J, Hamilton M et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole in young healthy male subjects. Aliment Pharmacology Ther 1998;12:1079-89.
4. Ohning G, Wlash, J, Pisegna J, et al. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment Pharmacology Ther 2003;17:1109-1114.
5. Stack W, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenter. 1998;95:1909-13.
6. Hawkey C, Atherton J, Trichel B, et al. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacology Ther. 2003;17:1065-4.
7. Thomson A, Chiba N, Sinclair P. From Bench to Bedside and back-Report on the European Helicobacter pylori Study Group Xth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Can J of Gastroenterol, Vol. 12, No. 6, September 1998: 437-446.
8. Labenz, J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Practice & Research Clinical Gastroenterology. 2001;15:413-31.
9. Hunt RH et all, Canadian Helicobacter pylori Consensus Conference Update: Infections in adults. Can J Gastroenterol, Vol.13, No.3, April 1999: 213-217.
SOURCE: Janssen-Ortho Inc
Canada Approves Proton Pump Inhibitor, Pariet (Rabeprazole), for Treatment of H. Pylori Infection
TORONTO, ON -- November 4, 2003 -- If you're suffering from painful ulcers, it may not be the spicy food that is to blame, but a type of ulcer-causing bacterium that is found in the gastrointestinal tract. Health Canada has just approved a new indication for Pariet* (rabeprazole sodium) tablets, a fast-acting prescription medication that is in a class called Proton Pump Inhibitors (PPI).
When taken in combination with appropriate antibiotics, Pariet* helps get rid of Helicobacter pylori (H. pylori), a bacterium that causes more than 90 per cent of ulcers of the small intestine.1 An estimated 20 to 40 per cent of the Canadian population carries the H. pylori bacterium in either their small intestine or stomach and an estimated 10 to 20 per cent (up to 2.5 million) of these people may develop clinically relevant disease requiring medical treatment.2
"Many of my patients complain of heartburn pain and discomfort from gastrointestinal problems, such as ulcers," says Dr. Lawrence Cohen, an associate professor of medicine at the University of Toronto. "Sometimes they think the pain is caused by spicy foods. Contrary to popular belief, eating certain foods does not cause ulcers. Ulcers can be caused by a more serious condition, such as H. pylori infection."
In acid suppression studies, Pariet* has shown that it is fast and effective.3,4 When used in combination with antibiotics to wipe out H. pylori associated with ulcers of the small intestine, Pariet* offers doctors and their patients an effective and safe treatment option when used according to its approved prescribing information.5,6
H. pylori
Researchers are not certain how people contract H. pylori, but they think it may be through food or water or through oral contact such as kissing.7 Getting rid of H. pylori in patients with ulcers of the small intestine facilitates healing, reduces the rate of recurrence and reduces the risk of ulcer bleeding.2 The stomach's lining contains millions of cells with "acid pumps" that help digest food. Proton Pump Inhibitors, or PPIs, work by decreasing the acid produced by these pumps, keeping acid production under control. Suppressing the acid that the stomach produces helps the antibiotics eliminate the H. pylori bacteria.8 In Canada, the recommended therapy for the eradication of H. pylori includes treatment with a Proton Pump Inhibitor and appropriate antibiotics.9
"Today, we know the importance of eradicating of H. pylori. Proton pump inhibitors, such as Pariet*, along with appropriate antibiotics, can successfully eradicate the infection in most patients and allow ulcers of the duodenum (the first part of the small intestine) to heal, as well as lower the chance of ulcers coming back," says Dr. Cohen.
Pariet*
Pariet* was first approved in Canada in May 2001 for the healing of stomach ulcers, duodenal ulcers, reflux esophagitis (a severe form of heartburn) and symptom relief of reflux conditions, such as heartburn and regurgitation. Pariet* tablets may also be used in rare conditions like "Zollinger-Ellison" syndrome, where the stomach produces large amounts of acid.
References:
1. Centers for Disease Control and Prevention (CDC) Electronic references. Retrieved July 22, 2003 from http://www.cdc.gov/ulcer/.
2. Chaun H. Update on the role of H pylori infection in gastrointestinal disorders. Can J Gastroenterol Vol. 15, No. 4, April 2001:251-255.
3. Williams MP, Sercombe J, Hamilton M et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole in young healthy male subjects. Aliment Pharmacology Ther 1998;12:1079-89.
4. Ohning G, Wlash, J, Pisegna J, et al. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment Pharmacology Ther 2003;17:1109-1114.
5. Stack W, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenter. 1998;95:1909-13.
6. Hawkey C, Atherton J, Trichel B, et al. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacology Ther. 2003;17:1065-4.
7. Thomson A, Chiba N, Sinclair P. From Bench to Bedside and back-Report on the European Helicobacter pylori Study Group Xth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Can J of Gastroenterol, Vol. 12, No. 6, September 1998: 437-446.
8. Labenz, J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Practice & Research Clinical Gastroenterology. 2001;15:413-31.
9. Hunt RH et all, Canadian Helicobacter pylori Consensus Conference Update: Infections in adults. Can J Gastroenterol, Vol.13, No.3, April 1999: 213-217.
SOURCE: Janssen-Ortho Inc
Comments
No comments yet. Leave a Comment